Sequenom and NAFTNet to Conduct Fetal Rhesus D Study in Collaboration with Baylor College of Medicine
Advertisement
Sequenom, Inc. announced that the Company will conduct a multi-center fetal Rhesus D (RhD) genotype study at centers affiliated with the North American Fetal Therapy Network (NAFTNet), a nonprofit research network with expertise in the care for pregnancies at high risk of complex fetal disorders. RhD testing will be conducted at Baylor College of medicine, Medical genetics Laboratory using a Laboratory Developed Test (LDT) with Sequenom's MassARRAY(R) system and SEQureDx(TM) Technology.
The prospective, multi-center study, which will enroll 550 pregnant women who are RhD negative, has two primary goals. First, Baylor College of Medicine intends to use Sequenom's SEQureDx Technology to validate its LDT assay for RhD for use as a clinical service offering. Second, samples collected from this study will later be used in clinical studies to support Sequenom's planned regulatory application to the U.S. Food and Drug Administration (FDA).
The study's principal investigator, Dr. Kenneth Moise, Professor of Obstetrics and Gynecology and Director of the Division of Maternal-Fetal Medicine at Baylor College of Medicine in Houston, commented, "This study will initially involve the enrollment of RhD-negative pregnant women from eight to 10 member institutions throughout the NAFTNet system. The ability to make an early diagnosis is the key that opens the door for the treatment of RhD incompatibility and other birth defects before a child is born."
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
LFE Laboratorium für industrielle Forschung GmbH & Co. Entwicklungs KG - Bruchköbel, Germany
Andromeda Biotech Successfully Completes Patient Recruitment in Phase III Trials for DiaPep277 for Type 1 Diabetes
Bonnie Bassler and Martin Wikelski receive Max Planck Research Award - Scientists honoured for their pioneering research into the sensory perception of organisms
Stora Enso and Gasum to make renewable energy from wastewater in Sweden
LDC and HZI enter partnership for the discovery of new drugs against multi-resistant bacteria
New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction
Generex Biotechnology and Pevion Biotech announce plans for immunotherapeutic vaccine collaboration
Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox - HalcyGen to begin Marketing Authorisation Application for Regulators in Europe
Eschbach receives the Best of Industry Award for Artificial Intelligence for the second time in a row - "AI technologies are increasingly becoming an integral part of process management..."
Antibiotic-Resistant Bacteria Have Evolved a Unique Chemical Mechanism, New Discovery Reveals
UF study strengthens concerns about long-term use of certain painkillers
